BioVersys AG
BioVersys is a Swiss pharmaceutical company dedicated to fighting antimicrobial resistance (AMR) through innovative research and development of small molecules targeting bacterial infections. The company focuses on developing novel antibiotics and therapies for serious, life-threatening infections caused by multi-drug resistant bacteria, with a mission to improve patient outcomes and address high unmet medical needs. The company is actively involved in clinical trials, including Phase 2a trials for BVL-GSK098, a novel compound developed in collaboration with GSK, targeting tuberculosis. BioVersys also engages in partnerships with organizations like TASK and the EU-funded RespiriNTM Programme to accelerate development of broad-spectrum drug candidates against NTM pulmonary diseases.
Industries
Nr. of Employees
small (1-50)
BioVersys AG
Products
Intravenous rifabutin-based clinical candidate
Clinical-stage intravenous formulation of a rifabutin-derived compound developed for severe hospital-acquired Gram-negative infections, with an uptake mechanism enabling intracellular delivery and demonstrated in vitro and in vivo activity against resistant isolates.
Transcriptional regulator potentiator for tuberculosis
First-in-class small-molecule potentiator that targets bacterial transcriptional regulators to augment and restore activity of an existing second-line TB antibiotic; progressed through Phase 1 and into Phase 2a EBA evaluation in combination with the partner antibiotic.
Preclinical antibacterial series (discovery-stage)
Discovery-stage antibacterial chemical series targeting nosocomial Gram-negative pathogens and nontuberculous mycobacteria, progressed through lead optimisation and preclinical profiling.
Intravenous rifabutin-based clinical candidate
Clinical-stage intravenous formulation of a rifabutin-derived compound developed for severe hospital-acquired Gram-negative infections, with an uptake mechanism enabling intracellular delivery and demonstrated in vitro and in vivo activity against resistant isolates.
Transcriptional regulator potentiator for tuberculosis
First-in-class small-molecule potentiator that targets bacterial transcriptional regulators to augment and restore activity of an existing second-line TB antibiotic; progressed through Phase 1 and into Phase 2a EBA evaluation in combination with the partner antibiotic.
Preclinical antibacterial series (discovery-stage)
Discovery-stage antibacterial chemical series targeting nosocomial Gram-negative pathogens and nontuberculous mycobacteria, progressed through lead optimisation and preclinical profiling.
Services
Collaborative preclinical discovery and validation
Partnered discovery programs with academic and industry collaborators to identify targets, perform medicinal chemistry, and conduct in vitro and in vivo validation to select preclinical candidates.
Clinical development and program management (Phase 1–2)
End-to-end design and conduct of early clinical trials including protocol development, clinical operations, PK/PD assessments, safety monitoring and regulatory interactions.
Translational screening platform services
Project-based translational studies combining characterised clinical isolates, non-mammalian in vivo models and imaging to provide rapid in vivo proof-of-concept and quantitative PD data for antimicrobial candidates.
Consortium-led Phase 2a EBA clinical trial execution
Delivery of Phase 2a early bactericidal activity trials in partnership with clinical research sites and consortium partners to assess efficacy, safety and PK of combination regimens in pulmonary TB patients.
Collaborative preclinical discovery and validation
Partnered discovery programs with academic and industry collaborators to identify targets, perform medicinal chemistry, and conduct in vitro and in vivo validation to select preclinical candidates.
Clinical development and program management (Phase 1–2)
End-to-end design and conduct of early clinical trials including protocol development, clinical operations, PK/PD assessments, safety monitoring and regulatory interactions.
Translational screening platform services
Project-based translational studies combining characterised clinical isolates, non-mammalian in vivo models and imaging to provide rapid in vivo proof-of-concept and quantitative PD data for antimicrobial candidates.
Consortium-led Phase 2a EBA clinical trial execution
Delivery of Phase 2a early bactericidal activity trials in partnership with clinical research sites and consortium partners to assess efficacy, safety and PK of combination regimens in pulmonary TB patients.
Expertise Areas
- Antibacterial small-molecule discovery
- Drug potentiator approaches to overcome antibiotic resistance
- Translational in vitro/in vivo modelling and imaging
- Preclinical GLP toxicology and IND-enabling studies
Key Technologies
- Transcriptional regulator–targeting small molecules
- Ansamycin-class medicinal chemistry
- Drug potentiator/antibiotic potentiation strategy
- Bioluminescent reporter bacterial strains